Douglas Macdonald
Affiliations: | CHDI Management |
Area:
Huntington's disease, biomarkers, gene therapy, gene silencing, GPCRs, mGluRs, Substance P, molecular pharmacology, TRK receptor, peptide synthesis,Google:
"Douglas Macdonald"Mean distance: 17.03 (cluster 32) | S | N | B | C | P |
Parents
Sign in to add mentor| Susan E. Leeman | grad student | CHDI Management | |
| R. Bruce Merrifield | research scientist | CHDI Management |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Macdonald D, Mierke DF, Li H, et al. (2001) Photoaffinity labeling of mutant neurokinin-1 receptors reveals additional structural features of the substance P/NK-1 receptor complex. Biochemistry. 40: 2530-9 |
| Li H, Macdonald DM, Hronowski X, et al. (2001) Further definition of the substance P (SP)/neurokinin-1 receptor complex. MET-174 is the site of photoinsertion p-benzoylphenylalanine4 SP. The Journal of Biological Chemistry. 276: 10589-93 |
| MacDonald D, Silberman SC, Lowe JA, et al. (1996) Photoaffinity labeling of the human substance P (neurokinin-1) receptor with [3H2]azido-CP-96,345, a photoreactive derivative of a nonpeptide antagonist. Molecular Pharmacology. 49: 808-13 |
| Unson CG, Macdonald D, Merrifield RB. (1993) The role of histidine-1 in glucagon action. Archives of Biochemistry and Biophysics. 300: 747-50 |
| Unson CG, Macdonald D, Ray K, et al. (1991) Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding. The Journal of Biological Chemistry. 266: 2763-6 |